Argenx Se (ARGX) Other Non Operating Income (2016 - 2026)
Argenx Se (ARGX) posted Other Non Operating Income of -$11.0 million for Q1 2026, down 31.53% on a QoQ basis from -$8.4 million in Q4 2025, and down 140.74% year-over-year from $27.0 million in Q1 2025.
Argenx Se (ARGX) Other Non Operating Income (2016 - 2026) Analysis & Trends
Argenx Se's Other Non Operating Income history runs 11 years deep, the most recent figure standing at -$11.0 million for Q1 2026.
- Quarterly Other Non Operating Income fell 140.74% year-over-year to -$11.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.4 million (up 1540.44% YoY) and the FY2025 annual result came in at $65.8 million, up 236.47% from the prior year.
- Other Non Operating Income was -$11.0 million for Q1 2026 at Argenx Se, down from -$8.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $60.3 million in Q4 2022 and bottomed at -$54.9 million in Q4 2024.
- A 5-year average of -$736235.3 and a median of -$7.2 million in 2022 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income slumped 542.15% — and 2025, when it jumped 714.51%.
- Argenx Se's Other Non Operating Income stood at $60.3 million in 2022, then sank by 37.9% to $37.4 million in 2023, then sank by 246.78% to -$54.9 million in 2024, then soared by 84.77% to -$8.4 million in 2025, then sank by 31.53% to -$11.0 million in 2026.
- Business Quant data shows ARGX's Other Non Operating Income at -$11.0 million in Q1 2026, -$8.4 million in Q4 2025, and -$1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.00 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -1.85 Mn |
| Jun 30, 2025 | 48.57 Mn |
| Mar 31, 2025 | 27.00 Mn |
| Dec 31, 2024 | -54.92 Mn |
| Sep 30, 2024 | 33.93 Mn |
| Jun 30, 2024 | -7.90 Mn |
| Mar 31, 2024 | -19.31 Mn |
| Dec 31, 2023 | 37.42 Mn |
| Sep 30, 2023 | -32.51 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | 11.17 Mn |
| Dec 31, 2022 | 60.26 Mn |
| Sep 30, 2022 | -39.61 Mn |
| Jun 30, 2022 | -46.17 Mn |
| Mar 31, 2022 | -7.21 Mn |
| Dec 31, 2021 | -14.06 Mn |
| Sep 30, 2021 | -17.62 Mn |
| Jun 30, 2021 | 10.44 Mn |